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Summary
Objectives: The aim of this research was to analyze the antibacterial drug consumption pattern
in a 1-million-plus strictly defined population in Poland. We assessed outpatient antibiotic sales
(ATC J01) in relation to patient age and season of the year, and sought to determine the group of
patients with the most frequent recurrence of bacterial diseases.
Methods: The Lubuskie Regional Unit of the National Health Fund (NHF) and the Central
Statistical Office (GUS) were the main sources of data. For the period 2002—2005, data on
outpatient sales of antibiotics (ATC J01) in Lubuskie Province were collected and expressed in DDD
(defined daily dose; World Health Organization anatomical therapeutic chemical (ATC)/DDD
version 2006) per 1000 inhabitants per day (DID).
Results: During the period 2002—2005, the average level of antibiotic use amounted to 19.8 DID
in the Lubuskie population. During the 3-year period, 64.3% of the population was treated with
antibiotics. This value varied for different age groups. Of the patients, 22.7% utilized 62.6% of a 3-
year supply of antibiotic therapy in the province; a small 1.9% of the population used 10.0% of the
supply. The seasonal variation of antibiotic consumption in different age groups showed a strong
tendency to be flatter as the older age groups were analyzed.
Conclusions: The data gained from the payers, i.e., the healthcare system, is a very valuable
source of information for pharmacoepidemiological studies. Our study shows that seasonal
variation in antibiotic use is strictly linked with the age of patients. Special attention should
be paid to the relatively small group of patients that utilizes a significant percentage of the year’s
supply. We have established an effective way to present recurrence data (a map showing the
infectious disease incidence). This could be a very useful tool for comparing antibiotic consump-
tion in different countries.
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484 D. Dziurda et al.IntroductionIn Poland, as in other countries, drug resistance in bacterial
pathogens is on the increase.1—4 This process is, to a large
extent, linked to the excessive, often unnecessary consump-
tion of antibiotics.5 The Polish National Health Fund (NHF), a
health insurance organization that forms the major public
source of healthcare financing, records a continuous increase
in spending on antibacterial treatment.6 This problem is of
interest to specialists in multiple healthcare disciplines.7,8 It
is also reflected in numerous publications attempting to
present the quantitative and qualitative trends in the use
of antibiotics in the treatment of different diseases.2,9 These
publications provide information about the level of consump-
tion of these drugs (using DDD (defined daily dose) metho-
dology), seasonal variations, and long-term trends in this
area of pharmacotherapy.
Available studies are based on a few basic types of data of
varying reliability: survey data, data provided by companies
analyzing the pharmaceutical market, insurance company
wholesale reports, as well as hospital and pharmacy records.
These sources provide general information referring to popu-
lations of entire countries or regions. There is a lack of in-
depth analyses of antibiotic utilization patterns within stu-
died populations. This probably stems from the difficulty of
acquiring reliable data that can fully describe drug consump-
tion in a large, closed population.10 Thus, the following
aspects remain unidentified: the level of consumption of
antibiotics and their seasonal variations in different age
groups, as well as identification of the patient population
having the key influence on the drug reimbursement system,
in relation to antibacterial pharmacotherapy.
The aim of this research was to analyze consumer behavior
in the area of antibacterial pharmacotherapy, based on the
large (1.009 million), closed population of Lubuskie Province
in Poland. The analysis was undertaken using data from the
Lubuskie Province Unit of the NHF. We aimed to determine
the relationship between antibacterial drug use, the fre-
quency of ambulatory treated infectious diseases, and the
age of patients. The unique character of the available data
enabled us to create a map representing the repetition of
antibacterial therapy.
Methods
Data
The following sources of information were used during this
research: data from the Lubuskie Regional Unit of the NHF11
and demographic data from the Central Statistical Office
(Gło´wny Urza˛d Statystyczny; GUS).12
The regional units of the NHF gather information on the
volume of sales of drugs eligible for reimbursement in order to
repay the pharmacies. In Lubuskie Province, the collected data
include a unique number (PESEL) identifying each patient who
has been prescribed a drug. This allows the tracking of the
reimburseddrug sales operation (SO) in relation toevery indivi-
dual patient.Data fromtheNHFusedfor this study includedthe
documentationofmedicationdispensedtotheoutpatientsinthe
years 2002—2005 in Lubuskie Province. In total, the authors
received approximately 25 million records. Each record corre-spondstoasinglesaleofareimburseddruginapharmacy(SO).Of
theserecords,3.2millionrefertothetherapeuticgroupATCJ01
(antibacterial for systemic use).
According to the demographic data, the analyzed popula-
tion amounts to 1.009 million inhabitants; this value did not
change by more than 0.1% during the study period. SO of the
reimbursed drug had been recorded for 0.975million patients
during the study period. For the purpose of the analysis 3.034
million records (SO) have been included, corresponding to
0.699 million patients.
The data used in this study, despite the different methods
of collection (potential information processing error) are
compatible with official publications from the NHF.13 Com-
paring the structure of consumption with data from the
whole of Poland, a lower use of furazidin and cefuroxime
pharmaceuticals in Lubuskie Province is noticeable. The
antibiotic consumption in the population of Lubuskie Pro-
vince is about 5% lower than the national average.14 Taking
this into consideration, we estimate the data as representa-
tive of the whole country.
Terms used
Sale operation (SO): refers to every single purchase of an
antibacterial drug by a patient.
Antibiotic therapy course (ABC): refers to a single case of
purchase of an antibacterial drug by a patient, each case
being separated by a 30-day period of time from one to
another. If in the defined period of time more than one
instance of an antibacterial drug sale occurred, it was trea-
ted as belonging to one course.
Recurrent courses of antibiotic therapy (RABC): the ana-
lysis of the recurrence of treatment was made for the period
August 2002—July 2005, divided into six 6-month sub-periods.
Six-month sub-periods were used in order to facilitate com-
prehension–—native data are available daily.
Statistical analysis
In the presentation of results the approximation of numbers
to the first digit after the decimal point has been used.
Microsoft Office components were used for data processing
as well as Statistica1 6.0 (StatSoft Inc.) and SPSS v.14 (SPSS
Inc.) packages.
The presentation of results is based on the anatomical
therapeutic chemical (ATC)/DDD classification system (World
Health Organization, ATC/DDD version 2006),15,16 expressed
in DDD per 1000 inhabitants per day (DID) as well as percen-
tage of total drug consumption (%DDD). The results referring
explicitly to the SO are expressed in SO per 1000 inhabitants
per day (SOID) as well as percentage of SO (%SO).
Results
The average level of antibiotic consumption in the population
of Lubuskie Province for the period 2002—2005, amounts to
19.8 DID. School-aged patients (5—19 years) rank above the
average, as well as people aged 60 years and over (Figure 1).
The maximum deviation from the estimated average occurs
for the oldest patients, those aged over 75 years.
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Figure 1 Average yearly antibiotic consumption in the different age groups. The average consumption level in the analyzed
population amounted to 19.8 DDD/1000 inhabitants/day (DID). Percentage values indicate deviation from average consumption in the
different age groups.A parallel analysis was made based on the criterion of
registered SO and the quantity of dispensed packages of drugs
(Figure 2). This revealed that 20—59-year-old patients are
characterized by a stable average SO equal to 1.6 SOID. The
amount gradually increases with patient age, reaching a level
of 3.1 SOID for patients over 80 years old. The highest number
of SO was recorded for patients under 10 years of age (5.4
SOID in the group of patients under 4 years of age). Using the
accumulated data (not presented in the figure) we can see
that the age group 0—9 years, while constituting only 10.2% of
the population, generated 23.6% of all recorded SO, whereas
the oldest group of patients (those aged 65 years-plus),
amounting to 11.6% of the population, generated 13.9% of
the total amount of this service.
The estimated seasonal fluctuations in consumption refer-
ring to the total population of the province (Figure 3) agreeFigure 2 Average yearly antibiotic registered sales operations (SO)
analyzed population amounted to 2.2 SO/1000 inhabitants/day (SOID)
different age groups. The data presented are almost equal to the
inhabitants/day).with available publications.2,17 The patient population is not
homogenous in terms of seasonal changes. In all age groups,
the months of greatest consumption are March and Decem-
ber, whilst the lowest consumption is recorded for the sum-
mer months: June, July, and August. The youngest patients
(0—4 years of age) show a significant peak in consumption at
the beginning of the winter season (December); the intake of
antibiotics in this month is 3.7 times higher than the con-
sumption in August. Children aged 5—9 years tend to have
two consumption peaks: the months of December and March.
They are higher than the yearly average for this age group by
58.2% and 68.6%, respectively. Patients aged 10—19 years
show a significant peak of consumption in March (3.1 times
higher than in July; 122.7% of the average yearly consump-
tion). The seasonal value curve shows a strong tendency to be
flatter as the older age groups are analyzed. Patients who arein the different age groups. The average consumption level in the
. Percentage values indicate deviation from the average SO in the
number of dispensed packages of medicines (packages/1000
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Figure 3 Comparison of seasonal variations in the consumption of antibiotics in the different age groups. The percentage deviation
from the yearly average was calculated separately in each age group case and for the whole population.
Figure 4 Yearly percentage of patients treated with antibacterial drugs in different age groups; average data for the 2002—2005
period.
Figure 5 Average percentage of antibiotic consumption by successive 10% groups of the 1-year treated population (YTP). Patients
were set in order of increasing yearly antibiotic consumption, and then divided into 10 equal groups (every 38 543 treated patients);
average data for every 1-year period (2002—2005) in DDD.
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when the level of consumption is 2.4 times higher than the
decreased consumption in August (March +52.1%, August
36.1% of the average age group consumption).
One can indirectly infer the incidence of ambulatory
treated infectious diseases based on ABC (Figure 4). The
average yearly incidence for patients in the age group 20—
59 years is on the level of 30.2% rising to 48.3% for the oldest
patients. The maximum is reached in the age group 5—9 years
(67.2%).
Using the DDDmethodology we attempted to estimate the
size of the high-consumption group. In every calendar year at
least one SO is recorded for an average of 38.2% of theFigure 6 Map of the 3-year incidence of recurrent courses of a
Subsequent horizontal layers show incidence history in respective
descending manner, according to the criterion of increasing frequ
structure of incidence (colored bar means occurrence of RABC in pe
facilitate comprehension of the data).Lubuskie Province population (0.385 million patients). They
constitute the yearly-treated population (YTP) correspond-
ing to the axis label in Figure 5. Ten percent of them used
30.9% DDD of the total antibiotics consumed, whereas 50%,
characterized by the lowest consumption level, used only
20.9% DDD of these medications (Figure 5).
The number of recurrent antibiotic therapy courses for
particular patients was calculated for a 3-year period
(according to the methods described) taking at least one
purchase of an antibiotic in a 6-month period as an RABC
occurrence. Medical visits resulting in the prescription and
subsequent purchase of an antibacterial drug were recorded
for 64.3% of the Lubuskie Province population during thentibiotic therapy (RABC) in the Lubuskie Province population.
patients. To facilitate legibility the patients are grouped in a
ency of incidence, into 63 categories of a differentiated time
riod of time: white bar = none, black and gray are used only to
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Table 1 Comparison of antibiotic use (DDD methodology)
and the number of sales operations during the 3-year period
of analysis in different groups of patients corresponding to
the classification presented in Figure 6
Number
of RABC
% of
patients a
% of
DDDb
% of
SOc
6 1.9 10.0 12.1
5 3.7 13.8 15.2
4 6.5 17.8 18.2
3 10.6 20.9 20.1
2 17.4 21.8 20.2
1 24.2 15.5 14.1
0 35.7 0 0
RABC, recurrent courses of antibiotic therapy; DDD, defined daily
dose; SO, sales operations.
a Population size 1.009 million people.
b Total consumption 23.69 million DDD.
c Total sales operations 2.74 million.period of analysis (Figure 6). Ten percent of the total 3-year
supply of antibacterial drugs was used for only 1.9% of
patients. Comparing the yearly data to the 3-year data,
we saw that 10% of the most frequently or most severely
ill patients utilized 59.6% and 35.2%, respectively, of the DDD
antibacterial drugs (cumulative data for the whole Lubuskie
Province population, not presented in Figure 6 or Table 1).
Discussion
The DDD methodology provides unquestionable advantages in
studies of drug use, ensuring the comparability of analyses
made in different countries. Despite its advantages, the DDD
methodology, as reported in numerous publications, fails to
accurately describe drug consumption in children.Differentia-
tion of consumption in different age groups presented in the
DDDmethodology does not exceed 48.9% deviation (the oldest
patients) from the average for the studied population. Using
the number of purchased medication packages or the fre-
quencyof theSOas theconsumption indicator, onecanobserve
139.8% deviation in the youngest group (0—4 years old).
These observations are corroborated by the analysis of the
yearly variations of antibiotic consumption in different age
groups. In the case of young patients, their caretakers expect
a quick recovery from the infection and the doctor is under
pressure to prescribe an antibacterial drug. A very significant
increase in antibiotic prescriptions in periods of epidemic
viral infections among the youngest patients as well as school
children, shows that the potentially most effective target
groups for education programs are the parents, caretakers,
and doctors.8
The key point of this study was the analysis of the con-
sumption level in a 1-year period and the creating of a map
showing the infectious disease incidence in a 3-year period of
time in a large, closed (over one million patients) population
(Figure 6).Wedemonstrated that a groupconstituting 22.7%of
the population is responsible for the use of 62.6% of a 3-year
supply of antibiotics in the province. Significantly, it was
possible to isolate the 1.9% of the population that used over
10% of these supplies, and to show an almost chronic use of
antibiotics. This subject requires a separate analysis. In gen-eral, the existence of a particularly frequently treated group,
therapeutically justified cases notwithstanding, might be
related to therapeutic errors, the identification of which will
trigger actions aimed at rationalizing the treatment to be
taken. Creation of the incidence map is, in the authors’
opinion, their unique contribution to the knowledge of con-
sumptionbehavior in the scopeof antibacterial pharmacother-
apy. Creating comparable studies inpopulations fromdifferent
countries aswell as the possibility of observing timelines in this
discipline would facilitate the drawing of broader conclusions
concerning the health of the society in question.
The data collected by the payers of the health system are
a very important source of information for pharmacoepide-
miological studies. The possible scope of conclusions based
on this data is directly related to the level of detail in the
collected information. The fact that the payer (NHF) is
centralized with most antibiotics eligible for reimbursement,
is crucial to the actions that need to be taken. Being cen-
tralized, the NHF is able to carry out reliable analyses of the
healthcare system and to create automated systems to
monitor pharmacotherapy in the future.
We are conscious of some bias in the information sources,
which has limited our research. The dataset used for this
study covers drugs permitted for sale in Poland and included
in the system as a reimbursed treatment. The system of
reimbursed treatment encompasses most of the J01 drugs
registered in Poland (98%). During the period of study, the
main differences as far as inclusion into the system of
refunded treatment was concerned, occurred in two groups:
J01E (sulfonamides and trimethoprim) and J01M (quinolone
antibacterials) of the ATC system. Most of the antibiotics that
are excluded from the refunded treatment system belong to
these two groups. The data concerning consumption of the
drugs belonging to these therapeutic groups might not reflect
the actual total consumption. The underestimation error
might apply to patients who made only one purchase of a
drug from the ATC J01 group during the study period and is
strictly linked to the data preprocessing methodology. The
weakness of the data from the insurance systems is a lack of
information about drugs outside of the reimbursement sys-
tem (patients without insurance, drug sale within the phar-
maceutical prescriptions).
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